دورية أكاديمية
أعرض في EDS

Two Difficult Pandemics: Tuberculosis and COVID-19.

التفاصيل البيبلوغرافية
العنوان: Two Difficult Pandemics: Tuberculosis and COVID-19.
المؤلفون: Katran ZY; Department of Allergy and Immunology, Süreyyapaşa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Babalık A; Department of Chest Diseases, Süreyyapaşa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Türkar A; Department of Radiology, Süreyyapaşa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Demir FK; Department of Chest Diseases, Süreyyapaşa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Çakmak B; Department of Chest Diseases, Süreyyapaşa Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
المصدر: International journal of mycobacteriology [Int J Mycobacteriol] 2024 Jan 01; Vol. 13 (1), pp. 28-33. Date of Electronic Publication: 2024 Mar 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Medknow Country of Publication: India NLM ID: 101615660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-554X (Electronic) Linking ISSN: 22125531 NLM ISO Abbreviation: Int J Mycobacteriol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2017>- : Mumbai, Maharashtra, India : Medknow
Original Publication: Amsterdam : Elsevier, [2012]-
مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/complications , Coinfection*/epidemiology , Coinfection*/microbiology , SARS-CoV-2*, Humans ; Male ; Middle Aged ; Female ; Adult ; Aged ; Tuberculosis/epidemiology ; Tuberculosis/drug therapy ; Tuberculosis/complications ; Antitubercular Agents/therapeutic use ; Tuberculosis, Pulmonary/epidemiology ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/complications ; Comorbidity ; Mycobacterium tuberculosis/isolation & purification ; Pandemics
مستخلص: Background: The coinfection of Mycobacterium tuberculosis and SARS-CoV-2 is called tuberculosis and COVID-19 coinfection (TB-COVID-19). We aimed to share the clinical, radiological, and laboratory findings and treatment processes of our patients with TB-COVID-19 coinfection in our tertiary reference hospital.
Methods: Patients aged 18 years and over and hospitalized in the tuberculosis service between March 2020 and September 2022 were included. All coinfected patients whose COVID-19 polymerase chain reaction results were positive while receiving tuberculosis treatment or who were diagnosed with tuberculosis while receiving treatment for COVID-19 were included.
Results: The number of patients was 39; 61.6% of males; the mean age was 52 ± 17.1 years; 20% were foreign nationals; 92.5% were Asian; 69.5% had a bacteriological diagnosis; 84.6% had pulmonary tuberculosis; 10% had received antituberculosis treatment before; and 87.5% were sensitive to the first-line antituberculosis drugs. The most common comorbidities were diabetes and hypertension. 87.5% of the patients were diagnosed with tuberculosis and were superinfected with COVID-19 while receiving tuberculosis treatment. 49.5% of patients had received at least one dose of COVID-19 vaccine. The most common presenting symptom was cough and sputum; the prominent laboratory parameter was C-reactive protein increase, and thorax computed tomography finding was consolidation, tree-in-bud, and cavitation. While 45.9% of the patients were still under treatment, 1 (2.5%) patient also resulted in mortality.
Conclusion: In this study, attention was drawn to two infectious diseases seen with respiratory tract symptoms. The mortality rate was found to be low. Neither disease was found to be a factor aggravating the course of each other.
(Copyright © 2024 Copyright: © 2024 International Journal of Mycobacteriology.)
References: Shariq M, Sheikh JA, Quadir N, Sharma N, Hasnain SE, Ehtesham NZ. COVID-19 and tuberculosis:The double whammy of respiratory pathogens. Eur Respir Rev 2022;31:210264.
TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. Eur Respir J. 2022 Mar 24;59:2102538. [doi: 10.1183/13993003.02538-2021]. (PMID: 10.1183/13993003.02538-2021)
Impact of the COVID-19 Pandemic on TB Detection and Mortality in 2020. Available from: https://www.who.int/publications/m/item/impactof-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020.[Last accessed on 2021 Mar 22].
Chakaya J, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO global tuberculosis 2021 report –Not so good news and turning the tide back to End TB. Int J Infect Dis 2022;124 Suppl 1:S26–9.
Jain VK, Iyengar KP, Samy DA, Vaishya R. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr 2020;14:1439–43.
Visca D, Ong CW, Tiberi S, Centis R, D'Ambrosio L, Chen B, et al. Tuberculosis and COVID-19 interaction:A review of biological, clinical and public health effects. Pulmonology 2021;27:151–65.
Wang Q, Guo S, Wei X, Dong Q, Xu N, Li H, et al. Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection:A systematic review and meta-analysis (from November 2019 to March 2021). BMJ Open 2022;12:e059396.
Nieto-Chumbipuma J, Silva-Reategui L, Fernandez-Giusti A, Barja-Ore J, Retamozo-Siancas Y, Mayta-Tovalino F. Scientometric analysis of the world scientific production on tuberculosis associated with COVID-19. Int J Mycobacteriol 2022;11:249–55.
Zumla A, George A, Sharma V, Herbert RH. Baroness Masham of Ilton, Oxley A, Oliver M. The WHO 2014 global tuberculosis report- -further to go. Lancet Glob Health 2015;3:e10–2. [doi: 10.1016/S2214-109X(14)70361-4].
Aghajani J, Farnia P, Farnia P, Ghanavi J, Saif S, Marjani M, et al. Effect of COVID-19 pandemic on incidence of mycobacterial diseases among suspected tuberculosis pulmonary patients in Tehran, Iran. Int J Mycobacteriol 2022;11:415–22.
Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J 2020;56:1708–2020.
Sookaromdee P, Joob B, Wiwanitkit V. COVID-19 coinfection with Mycobacterium abscessus:A note. Int J Mycobacteriol 2022;11:339–40.
Song WM, Zhao JY, Zhang QY, Liu SQ, Zhu XH, An QQ, et al. COVID-19 and tuberculosis coinfection:An overview of case reports/case series and meta-analysis. Front Med (Lausanne) 2021;8:657006.
Koupaei M, Naimi A, Moafi N, Mohammadi P, Tabatabaei FS, Ghazizadeh S, et al. Clinical characteristics, diagnosis, treatment, and mortality rate of TB/COVID-19 coinfectetd patients:A systematic review. Front Med (Lausanne) 2021;8:740593.
Mollalign H, Chala D, Beyene D. Clinical features and treatment outcome of coronavirus and tuberculosis co-ınfected patients:A systematic review of case reports. Infect Drug Resist 2022;15:4037–46.
Up to Date. Approach to the Adult with Lymphocytosis or lymphocytopenialiterature Review Current through; 2022. Available from: https://www.uptodate.com/contents/approach-to-the-adult-withlymphocytosis-or-lymphocytopenia. [Last updated on 2022 May 03].
Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19):Systematic review and meta-analysis. J Intensive Care 2020;8:36.
Patil S, Gondhali G. COVID-19 pneumonia with pulmonary tuberculosis:Double trouble. Int J Mycobacteriol 2021;10:206–9.
Saghir SA, AlGabri NA, Alagawany MM, Attia YA, Alyileili SR, Elnesr SS, et al. Chloroquine and hydroxychloroquine for the prevention and treatment of COVID-19:A fiction, hope or hype? An updated review. Ther Clin Risk Manag 2021;17:371–87.
Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis 2020;101:138–48.
Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections:A systematic review and meta-analyses. J Med Virol 2021;93:2385–95.
تواريخ الأحداث: Date Created: 20240521 Date Completed: 20240521 Latest Revision: 20240521
رمز التحديث: 20240521
DOI: 10.4103/ijmy.ijmy_189_23
PMID: 38771276
قاعدة البيانات: MEDLINE
الوصف
تدمد:2212-554X
DOI:10.4103/ijmy.ijmy_189_23